TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?

Heart failure with preserved ejection fraction (HFpEF) continues to be a challenging form of heart failure – one in which no therapy has yet been proven to improve outcome. Aldosterone antagonists have previously been shown to improve survival in a wide spectrum of patients with heart failure with r...

Descripción completa

Detalles Bibliográficos
Autor principal: ElGuindy, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bloomsbury Qatar Foundation Journals 2013
Materias:
Lessons from the Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991207/
https://www.ncbi.nlm.nih.gov/pubmed/24749108
http://dx.doi.org/10.5339/gcsp.2013.42
_version_ 1782312395184537600
author ElGuindy, Ahmed M.
author_facet ElGuindy, Ahmed M.
author_sort ElGuindy, Ahmed M.
collection PubMed
description Heart failure with preserved ejection fraction (HFpEF) continues to be a challenging form of heart failure – one in which no therapy has yet been proven to improve outcome. Aldosterone antagonists have previously been shown to improve survival in a wide spectrum of patients with heart failure with reduced ejection fraction (HFrEF), and more recently, small trials suggested that they might have role in HFpEF patients. The effect of spironolactone on clinical outcomes in HFpEF was tested in the TOPCAT study.
format Online
Article
Text
id pubmed-3991207
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Bloomsbury Qatar Foundation Journals
record_format MEDLINE/PubMed
spelling pubmed-39912072014-04-18 TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF? ElGuindy, Ahmed M. Glob Cardiol Sci Pract Lessons from the Trials Heart failure with preserved ejection fraction (HFpEF) continues to be a challenging form of heart failure – one in which no therapy has yet been proven to improve outcome. Aldosterone antagonists have previously been shown to improve survival in a wide spectrum of patients with heart failure with reduced ejection fraction (HFrEF), and more recently, small trials suggested that they might have role in HFpEF patients. The effect of spironolactone on clinical outcomes in HFpEF was tested in the TOPCAT study. Bloomsbury Qatar Foundation Journals 2013-12-30 /pmc/articles/PMC3991207/ /pubmed/24749108 http://dx.doi.org/10.5339/gcsp.2013.42 Text en © 2013 ElGuindy, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 3.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Lessons from the Trials
ElGuindy, Ahmed M.
TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
title TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
title_full TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
title_fullStr TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
title_full_unstemmed TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
title_short TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
title_sort topcat misses its primary endpoint: should spironolactone be abandoned in hfpef?
topic Lessons from the Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991207/
https://www.ncbi.nlm.nih.gov/pubmed/24749108
http://dx.doi.org/10.5339/gcsp.2013.42
work_keys_str_mv AT elguindyahmedm topcatmissesitsprimaryendpointshouldspironolactonebeabandonedinhfpef

Ejemplares similares